Knowledge Library

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor.  This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Immunology Oncology Tumor Models

VIEW

Expanded Applications of PDX Models

Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. WuXi AppTec offers a comprehensive platform of more than 1,400 well-annotated PDXs across 30 cancer types. We also provide expanded in vitro, ex …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays Oncology Tumor Models

VIEW

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held this year in San Diego, CA, USA. As one of the most influential international conferences dedicated to cancer immunotherapy, SITC provides attendees with a cross-disciplinary educational and interactive platform. This meeting focuses on discussing and …Read More >

Resource Type: Article Blog
Resource Topic: Antibodies Autoimmune and Inflammatory Diseases Cell-based Assays in vivo Pharmacology Oligonucleotides Oncology

VIEW

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Cell-based Assays Oligonucleotides Oncology Tumor Models

VIEW

Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant non-small cell lung cancer. However, despite Enhertu’s clinical benefits, most patients inevitably experience disease progression and mortality. Understanding drug resistance mechanisms can aid in developing new treatment strategies for drug-resistant clinical patients. In this study, …Read More >

Resource Type: Latest Science Poster
Resource Topic: Cell-based Assays Oncology

VIEW

OncoWuXi Express: In Vitro Hydrogel-based 3D Tumor Models

Introduction: Over the last few years, the clinical success of immune checkpoint inhibitors has increasingly drawn attention to cancer therapies that target the tumor microenvironment (TME). TME consists of various cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells, and cancer associated fibroblasts, all of which play critical roles …Read More >

Resource Type: Article Blog
Resource Topic: Cell-based Assays Oncology

VIEW

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

DNA-dependent protein kinase (DNA-PK) plays an important role in the overall survival and proliferation of cells, making this enzyme an intriguing target for the treatment of a variety of cancers.  In our latest publication, WuXi AppTec scientists contributed to the discovery and characterization of ZL-2201, a potent and highly selective small molecule DNA-PK inhibitor.  In …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Hit-to-Lead Lead Optimization Oncology Tumor Models

VIEW

OncoWuXi Express: Large-scale Cell Panel Screening Platform for Integrated Pharmacogenomics and Bioinformatics Research

Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our large-scale cell panel screening platform for integrated pharmacogenomics and bioinformatics research. Cell viability assessment is a commonly used in …Read More >

Resource Type: Article Blog Case Study
Resource Topic: Cell-based Assays Hit-to-Lead Lead Optimization Oncology

VIEW

Anti-Tumor Nucleic Acid Drug Discovery Platform

Successful application of nucleic acid therapeutics faces many challenges, including delivery efficiency and off-target effects.  To address these challenges, WuXi AppTec offers a full suite of nucleic acid-related services, including target validation, in vitro screening and cell-based functional assays, drug exposure analysis, biodistribution evaluation, PK/PD/efficacy testing, and safety assessment.  Leverage our comprehensive platform to accelerate …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays in vivo Pharmacology in vivo Toxicology Oligonucleotides Oncology

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!